DC Funds, LP
Long book
$1.5M
Q1 2026
Positions
3
Top-10 weight
100%
concentration
Last quarter
-15.2%
SPY +14.8%
Turnover
0%
of book per quarter
Strategy in plain words
auto-generated from filingsDC Funds, LP is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $1.5M US long book across 3 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: TSCAN THERAPEUTICS INC, WEREWOLF THERAPEUTICS INC, BARINTHUS BIOTHERAPEUTICS PL.
Over the last 9 quarters its long book ran on average 20.7pp per quarter behind the S&P 500, beating the index in 2 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-41.8%
Q2 2024
-14.5%
Q3 2024
-30.8%
Q4 2024
-42.0%
Q1 2025
+4.2%
Q2 2025
+44.5%
Q3 2025
-53.3%
Q4 2025
+2.7%
Q1 2026
-15.2%
Sector allocation
Healthcare 100%
Long book by quarter
What does DC Funds, own?
Q1 2026 13F13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 3 | $1.5M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 3 | $1.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 10, 2025 | 3 | $3.1M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 3 | $2.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 3 | $2.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 3 | $3.6M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 3 | $5.2M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 3 | $6.0M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 3 | $10.3M | canonical | SEC ↗ |